Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

In a randomized pilot study recently published in the Journal for ImmunoTherapy of Cancer, an international research team led ...

Corticosteroid use, particularly at high doses, decreases the effectiveness of ICI therapy in patients with non–small cell ...